Dr Simó Schwartz Jr (1967th, Barcelona) is Director and Board member of CIBBIM-Nanomedicine, which fosters research on new biomedical advanced therapies and nanotechnology-based applications for the clinical practice. In particular, advanced cell therapies, new biomaterials and drug delivery systems, image based diagnostic systems and preclinical validation of therapeutic conjugates and bio-nanosensors, mainly in the areas of oncology and rare diseases. He is also member of the Science Advisory Board of the Vall d’Hebron Research Institute (VHIR) and member of the Science Advisory Board of the European Nanomedicine Characterization Laboratory (EU-NCL). He also leads the “drug delivery and targeting group” at the CIBBIM-Nanomedicine. He helds 14 patents, most transfered to leading companies of the biotech and pharma sectors and coauthors more than 90 papers in high impact factor journals. Dr Schwartz Jr is coordinator and collaborator of several research projects directly related with the obtention and validation of therapeutic drug delivery systems. Among them are international and EU projects involving SME’s in which animal models are being used for preclinical validation of new therapies directed against tumor cells. Dr Schwartz Jr is also member of the Nanomedicine Spanish Platform (NanomedSpain) and of the “European Platform for Nanomedicine”. His research group is also a group member of the “CIBER de Bioingeniería, Biomateriales y Nanomedicina” (CIBER-BBN) of the Spanish Health Institute CarlosIII (ISCIII) which gathers a total of 45 research groups of national excellence in the field of nanotechnology and nanomedicine. Dr Schwartz Jr was the Nanomedicine Coordinador of CIBER-BBN at the national level and later appointed as Deputy Director and technology transfer coordinator. Dr Schwartz was Co-founder and Science Advisor of ARGON Pharma SL (2008-2015), a Spin-Off company at the Barcelona Science Park with the mission to develop innovative therapies for unmet medical needs in oncology, and also to develop new technologies for drug delivery and diagnosis to improve current therapies. Dr Schwartz Jr is also member of the editorial Board of Precision Nanomedicine and until recently, of Eur. J. Nanomedicine and Nanomedicine-NBM. Eventual Science Advisor and Consultant of SOM BIOTECH and CELGENE. Former member of the Advisory Board of The Lundbeck Foundation Center of Excellence NanoCAN (Nanomedicine Research Center for Cancer Stem Cell Targeting Therapeutics), Southern Denmark University. Recently appointed as President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine.